Form 4: Precision Biosciences CFO Granted Significant Restricted Stock Units

Precision Biosciences, Inc. Chief Financial Officer John Alexander Kelly was granted 82,750 restricted stock units on June 2, 2025, as reported in a recent SEC Form 4 filing.

Summary

• John Alexander Kelly, Chief Financial Officer of Precision Biosciences Inc. (DTIL), acquired 82,750 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 2, 2025.
• Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
• The award is scheduled to vest in three substantially equal annual installments, with the first vesting date commencing on February 17, 2026.
• Vesting of the RSUs is contingent upon Mr. Kelly's continued service to Precision Biosciences through the applicable vesting dates.
• Following this reported transaction, Mr. Kelly beneficially owns 82,750 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive signal, indicating management retention and alignment with long-term company performance. It's a standard compensation practice, so not exceptionally positive, but certainly not negative.

Positives

• The grant of 82,750 Restricted Stock Units to the Chief Financial Officer aligns management's interests with long-term shareholder value, as the vesting is tied to continued service and future company performance.
• This equity grant serves as a significant incentive for the CFO to remain with the company and contribute to its strategic objectives and financial success.

Risks

• The vesting of the restricted stock units is subject to the Reporting Person's continued service to the Issuer, meaning the shares are not immediately owned and could be forfeited if employment ceases before the vesting dates.

Future Outlook

The grant of restricted stock units with a multi-year vesting schedule indicates an expectation of continued service from the Chief Financial Officer and aligns his incentives with the company's long-term performance and shareholder value creation.

Management Comments

• The filing indicates that the award vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Industry Context

Equity compensation, particularly through restricted stock units, is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This practice aligns executive interests with long-term company performance, which is crucial in an industry characterized by long development cycles and significant R&D investments.

Comparison to Industry Standards

• The grant of restricted stock units to a Chief Financial Officer is a standard form of executive compensation across various industries, including biotechnology, to foster long-term commitment and align executive interests with shareholder value.
• The vesting schedule over multiple years (starting February 2026) is typical for such grants, comparable to practices seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their executive compensation plans, which often include multi-year vesting periods to ensure retention and performance.
• The 'zero price' for RSUs is standard, as they represent a right to receive shares upon vesting, rather than an option to purchase shares at a set price.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's interests with long-term shareholder value through equity ownership and performance incentives.
• Employees: This grant is part of executive compensation, which can set a precedent or reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Future Form 4 filings will be required upon the vesting of these restricted stock units and subsequent conversion into common stock, or any other changes in beneficial ownership by John Alexander Kelly.

Key Dates

Keywords

Precision Biosciences, DTIL, Form 4, Restricted Stock Units, RSU, Insider Transaction, Equity Compensation, CFO, John Alexander Kelly, Biotechnology, SEC Filing